AGMB-129 has been designed to inhibit ALK5 in the gastrointestinal tract. Credit: sdecorated/Shutterstock.com.

Agomab Therapeutics has received the US Food and Drug Administration (FDA)’s fast track designation for AGMB-129 to treat fibrostenosing Crohn’s disease (FSCD).

Designed to inhibit ALK5 in the gastrointestinal (GI) tract, AGMB-129 is an oral, small molecule GI-restricted ALK5 (TGF-βRI) inhibitor currently in clinical development.

The single and multiple-dose AGMB-129 was well-tolerated at all doses in a Phase I study in healthy participants.

The company has also announced the commencement of the STENOVA Phase IIa clinical study to assess AGMB-129 for patients with symptomatic FSCD.

This global, placebo-controlled, multi-centre, double-blind study will assess 36 patients with symptomatic FSCD at investigational sites in Europe, Canada and the US.

See Also:

Subjects will be randomised to receive one of two doses of AGMB-129 or a placebo for a period of 12 weeks.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Tolerability and safety of AGMB-129 in FSCD patients are the primary endpoints of the trial. The pharmacokinetics and target engagement at the site of the ileal strictures are included as the secondary endpoints.

Agomab Therapeutics chief medical officer Philippe Wiesel stated: “The start of this Phase IIa clinical study is an important milestone in the development of AGMB-129.

“Intestinal strictures cause severe obstructive symptoms, are thought to induce fistulae formation and are the main cause of bowel surgery.

“Receiving the first FDA fast track designation in FSCD indicates that the FDA acknowledges the severity and unmet medical need in this indication.”